Proactive Investors - Run By Investors For Investors

Cash generative Alliance Pharma poised for further growth

The specialty pharmaceutical company generated over £11mln of cash
strips of pills
The company is looking for additions to its medicine chest

Alliance Pharma plc (LON:APH) is “strategically positioned for growth” following last year’s acquisition of the healthcare assets of Sinclair Pharma, according to chairman Andrew Smith.

His assessment was made alongside interim results, which showed revenue up 8% at £50.3mln and underlying earnings (EBITDA) ahead 3% at £13.6mln in the six months to June 30. Investors were rewarded with a 10% hike to the dividend, which rises to 0.443p.

The specialty pharmaceutical company generated over £11mln of cash, while net debt fell £12.7mln to £63.4mln in the period – equating to 2.4-times EBITDA.

The decline in borrowings provides Alliance with the financial headroom to go out and add more products to its medicine chest.

Integration complete

“With the integration of the Sinclair Pharma products now complete we are strategically positioned for growth and, with leverage levels reducing, we are now able to pursue bolt-on acquisitions," said chairman Smith.

Stand out in the results were the respective performances of the businesses’ two global products – Kelo-cote for scar reduction and MacuShield, used to treat an eye condition called age-related macular degeneration.

Sales of the former rose 52% to £6.2mln, while revenues for the latter were £3.4mln, up 67%.

There was supposed to be a third international product, Diclectin, for nausea during pregnancy, but it failed to gain UK regulatory sign-off.

READ: Alliance Pharma - a business in rude health

New opportunities

While a blow to Alliance’s plans, the short-term financial impact will be negligible, analysts say.

“Diclectin is a much-needed product as there is no licensed medicine for treating nausea and vomiting of pregnancy in the UK,” the company said.

“At this stage we expect these discussions to continue well into 2018 and, in the meantime, we will re-direct our commercial resources to other important growth projects within Alliance.”

It leaves Alliance looking for a Diclectin replacement, which is likely to come via acquisition or in-licensing rather from within the current portfolio.

READ: Alliance Pharma buy-and-build strategy working

The broker Numis said Alliance is on track to achieve revenues of around £103mln for the full-year, giving pretax profit of £24mln.

It said the continued reduction in debt would allow the company to ‘kick-start’ its buy and build strategy next year.

The shares, up 1.4% at 53.25p, are worth 60p each, according to analyst Sally Taylor.  

---adds share price and broker comment---

View full APH profile View Profile

Alliance Pharma plc Timeline

February 08 2018
February 08 2018
January 22 2018
January 02 2018
January 02 2018
December 22 2017
July 31 2017

Related Articles

mri scanner
January 31 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntingdon’s and multiple sclerosis
worried man on bed
October 16 2017
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”
picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use